Cardima gets Canadian nod for AF (atrial fibrillation) mictrocatheters:
This article was originally published in Clinica
Executive Summary
Cardima has gained the green light in Canada to market its REVELATION family of ablation microcatheters as a treatment for atrial fibrillation (AF). The Revelation Tx, Revelation T-Flex and Revelation Helix microcatheters can be used in a minimally invasive version of a surgical treatment for AF, called MAZE. They allow surgeons to create straight, curved and circumferential linear endocardial lesions to treat the condition. Cardima, of Fremont, California has already submitted a marketing application to the US FDA for the Revelation Tx device.
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.